Editorial
717 Joint space narrowing, cartilage and physical function: are we deceived by measurements and distributions?
R Landewé, D van der Heijde

Viewpoint
719 Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment
C S Consonni, S E Gabriel

Recommendation
722 European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects

Review
727 Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes
A Hao, P Moussou

Clinical and epidemiological research
733 Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction
D Alataha, J Fanovius, J S Smolen

740 Validation of a numerical rating scale to assess functional impairment in hip and knee osteoarthritis: comparison with the WOMAC function scale
P Ormest, M Dougados, S Paterno, E Legend, L Cosses

747 A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANA/JS trial)
P Quartier, F Allantaz, L Biasucci, M Hermann, S Lohmander, M Scholte-Voshaar, P Richards, C Ziegler, T A Abma

755 Effectiveness and safety of the interleukin 6-receptor antagonist tocolizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase lllb real-life study (TAMARA)
G R Buremst, E Feedt, H Kuller, J Braun, C Ilgen-Koren, A Roon-Roth

760 Lupus Atherosclerosis Prevention Study (LAPS)
M A Pen, A N Kian, W Post, L Christopher-Stine, L S Maegde

766 Cardiac dysfunction in juvenile dermatomyositis: a case-control study
T Schwartz, H Sanner, T Husebye, B Flatø, I Sjaastad

772 Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase
M G H van der Sande, M J H de Haar, C v a n der Leij, P L Klarenbeek, W H Bos, M D Smith, M Maas, N de Vries, D van Schadewijc, B A C Delfmans, D M Gertler, P P Tak

778 Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial
C C Moe, K Y Ying, C H To, L Ym Ho, K L Yu, H K Lee, K M Ma

785 High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis
K A, G Reed, J R Curtis, J M Kremer, D Greenberg, V Strand, D E Faust, on behalf of the CORRONA Investigators

792 Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments
B Salem, A K Brown, H Keen, S Nizam, J Freestem, R Widerfeld, Z Karm, M Quinn, E Hensor, P G Canaghian, P Emery

805 Assessment of synovitis with contrast-enhanced MRI using a whole-joint semiquantitative scoring system in people with, or at high risk of, knee osteoarthritis: the MOST A Gruenmatt, W F Becremer, D Hayashi, M D Cerna, J Niu, Y Zhang, M D Mann, A Kanau, J A Lynch, G Y El-Khouri, K Bate, L B Hughes, M C Nevin, D T Felom

812 Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study
S A Provan, A G Semb, J Hojel, E Stranden, S Agewall, H Davidson, K Angel, J K Astr, T K Kien

818 The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel
Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register
S M M Verstappen, Y King, R D Watson, D P M Symmons, R L Hynd, BSRBR Control Centre Consortium, BSR Biologics Register

A model for the development and implementation of a national plan for the optimal management of early spondyloarthritis: the Esperanza Program
S Muñoz-Fernández, L Carmona, E Collantes, J Mulero, M J García-Yébenes, E de Miguel, R Almodovar, C Fernández-Cataldo, J F G Llorente, M Coble, the Esperanza Group

Basic and translational research

Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis

HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus
N Page, F Gros, N Schall, M Dicosimo, D Bagnard, J-P Briand, S Muller

Role of oxidative stress in rheumatoid arthritis: insights from the Nrf2-knockout mice
C J Wruck, A Fregotelli, A Gurzynski, L-O Brandenburg, Y W Kan, K Chan, J Hanssenfling, S Freitag-Wolf, D Varoga, S Lippsios, T Pafe

The infrapatellar fat pad of patients with osteoarthritis has an inflammatory phenotype

Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis
M Carr, D L Boyd, L M Ronacher, B R Lew, L G van Baarsen, P P Tak, G S Firestein

Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study

Expansion of myelin autoreactive CD8+ T lymphocytes in patients with neuropsychiatric systemic lupus erythematosus
C Comin-Bordes, E Lazaro, C Richez, C Jacquemin, O Cauher, I Deucher, J-F Viardot, J-F Moreau, J-L Pellegrin, P Blanco

Letters

Sleep problems are of higher priority for improvement for patients with ankylosing spondylitis than for patients with other inflammatory arthropathies
T Heiberg, E Løs, D van der Heijde, T K Kvien

The GDF5 rs143383 polymorphism is associated with osteoarthritis of the knee with genome-wide statistical significance

Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis
A Jamnitski, I M Visman, M J Ester, M Beers, B A C Diplemans, M T Nurmohamed

Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
E E A Arns, T L Jansen, A Der Breede, H E Venkstein, E Dummer, M A F J Van de Laar, P L C M Van Riel, J Fransen

Serum levels of interferon α do not correlate with disease activity in patients with dermatomyositis/polymyositis
P Keil, O Kryštůfková, M Polankář, H Mann, M Klein, O Beate, J Venclovský